Trends in Use and Expenditures of Brand-name Atorvastatin After Introduction of Generic Atorvastatin

Haider J Warraich; Joseph A Salami; Rohan Khera; Javier Valero-Elizondo; Victor Okunrintemi; Khurram Nasir

doi:10.1001/jamainternmed.2018.0990

Trends in Use and Expenditures of Brand-name Atorvastatin After Introduction of Generic Atorvastatin

JAMA Intern Med. 2018 May 1;178(5):719-721. doi: 10.1001/jamainternmed.2018.0990.

Authors

Haider J Warraich¹, Joseph A Salami², Rohan Khera³, Javier Valero-Elizondo², Victor Okunrintemi², Khurram Nasir⁴

Affiliations

¹ Cardiology Division, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
² Center for Healthcare Advancement and Outcomes, Baptist Health South Florida, Miami.
³ Division of Cardiology, Department of Medicine, UT Southwestern Medical Center, Dallas, Texas.
⁴ Section of Cardiovascular Medicine, Yale School of Medicine, Center for Outcomes Research and Evaluation, Yale University and Yale New Haven Health System, New Haven, Connecticut.

Abstract

This study uses the Medical Expenditure Panel Survey (MEPS) database to analyze trends in use and expenditures of brand-name atorvastin after generic atorvastatin became available.

MeSH terms

Adult
Aged
Atorvastatin / economics*
Atorvastatin / therapeutic use*
Databases, Factual
Drugs, Generic / economics
Drugs, Generic / therapeutic use
Economic Competition
Female
Health Expenditures / trends*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / economics*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Longitudinal Studies
Male
Middle Aged
Prescription Drugs / economics*
Prescription Drugs / therapeutic use*
United States

Substances

Drugs, Generic
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Prescription Drugs
Atorvastatin